Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
BMC Complementary Medicine and Therapies|April 30, 2024
Anticancer properties and metabolomic profiling of Shorea roxburghii extracts toward gastrointestinal cancer cell linesSutthiwan Janthamala, Bundit Promraksa, Malinee Thanee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 17, 2025
Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathwayRattanaporn Jaidee, Piman Pocasap, Apinya Jusakul, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 14, 2013
Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinomaApinya Jusakul, Narong Khuntikeo, W Geoffrey Haigh, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for CholangiocarcinomaPreawwalee Wintachai, Jing Quan Lim, Anchalee Techasen, et al.
Plos One|September 25, 2025
A circulating microRNA panel enhances the diagnosis of cholangiocarcinomaAye Myat Mon, Kitti Intuyod, Sirinapha Klungsaeng, et al.
Scientific Reports|December 17, 2023
Overexpression of microRNA-205-5p promotes cholangiocarcinoma growth by reducing expression of homeodomain-interacting protein kinase 3Aye Myat Mon, Kitti Intuyod, Sirinapha Klungsaeng, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 29, 2022
Serum α2,6-sialylated glycoform of serotransferrin as a glycobiomarker for diagnosis and prediction of clinical severity in cholangiocarcinomaPhongsaran Kimawaha, Raynoo Thanan, Apinya Jusakul, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 8, 2017
Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in ThailandSunitta Saensa-Ard, Saman Leuangwattanawanit, Laddawan Senggunprai, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 17, 2024
Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistanceWaleeporn Kaewlert, Chadamas Sakonsinsiri, Worachart Lert-Itthiporn, et al.
Anticancer Research|January 31, 2025
Characterization of Patient-derived Xenograft Models of Liver Fluke-associated Cholangiocarcinoma: From Establishment to Molecular ProfilingHasaya Dokduang, Apiwat Jarernrat, Attapol Titapun, et al.
Pageof 6